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Table 1. HCT data.
OBu IVBu Global p
N 23 43 66
Age 23 (21-62) 39 (8-71) 45 ( 8-71) 0.08
Graft Failure 1 (4,3%) 3 (7%) 4 (6%) 0.56
Neutrophil recovery (days) 17 (8-42) 17 (0-61) 17 (0-61) 0.95
Platelet recovery (days) 22 (11-77) 20 (0-116) 21 (0-116) 0.04
GVHD Acute 6 (26%) 9 (21%) 23 % 0.42
GVHD Chronic 4 (17%) 13 (30%) 26% 0.20
EVOH 5 (21%) 3 (7%) 8 (12 %) 0.08
Hepatotoxicity 9 (47%) 6 (27%) 15 (23%) 0.20
Relapse 3 (13%) 12 (28%) 15 (23%) 0.20
Death 14 ( 60%) 21 (48%) 35 (53%) 0.44
Progression 3 (13%) 9 (21%) 12 (18%) 0.37
GVHD 4 (17%) 4 (9%) 8 (12%) 0.37
Infection 4 (17%) 4 (9%) 9 (14%) 0.37
EVOH 2 (8%) 1 (2%) 3 (4%) 0.37
Univariate Chi-Square Test.
S314 Poster Session IIAlthough RIC AHPCT can be performed as an outpatient, many
pts who receive this therapy still are later hospitalized. An assessment
of predictive factors prior to transplant would be useful to help de-
velop strategies to reduce hospitalizations after outpatient RIC
AHPCT as well as to counsel pts further regarding post-transplant
risk.We retrospectively evaluated 132 consecutive adult pts with he-
matologic diseases who received RIC AHPCT at our institution
from 1/2000-12/2009. Pts received fludarabine and either 200 cGy
(N5 45) or 400 cGy (N5 87) TBI. GVHD prophylaxis: mycophe-
nolate and either cyclosporine for those with related donors (N5 79)
or tacrolimus for those with unrelated donors (N5 53). Median age
was 57 years (range, 18-70) and 78 were males. Diagnoses included
73 myeloid and 55 lymphoid malignancies and 4 hematologic dis-
eases. 92 had no HLA disparate donor, 12 had an HLA disparity at
HLA-A, B, C or DRB1 (major), and 28 had an HLA disparity at
HLA-DQ or DP (minor). CIBMTR comorbidity index (CI): 51
low, 43 intermediate and 38 high risk pts. 120 (90%) were hospital-
ized post transplant at a median of 14 days (range, day 0 to +475) and
the most common reasons were: 72 fevers, 46 infections and 19 acute
GVHD. Risk factors for hospitalization were assessed by Cox pro-
portional hazards analysis. Variables included gender, age, CI, no.
prior chemotherapies, prior radiation, diagnosis, TBI dose, donor
relationship,HLAdisparities, TNC/CD34+ doses and time of trans-
plant relative to the 1st one on 1/10/00. From the univariable anal-
ysis the no. of prior chemotherapies, TBI dose, unrelated donor
and HLA disparity were associated with an increased risk for hospi-
talization, while a larger TNC dose was associated with a lower risk.
In multivariable analysis 2 variables remained prognostic: 400 cGy
TBI (p 5 0.026) and HLA disparity [minor/none; p\ 0.001; ma-
jor/none; p 5 0.07]. Although the majority of pts received 400
cGy TBI, we previously did not find a difference in time to neutro-
phil engraftment compared to those receiving 200 cGyTBI (Sobecks
et al. BMT 2008;42:715-22). We conclude that HLA disparities and
400 cGyTBImay delay immune reconstitution resulting in more in-
fections that require hospitalization after RIC AHPCT. Future
strategies to enhance immune reconstitution after this approach
are warranted and if effective may have important implications re-
garding reductions in expenses and healthcare resources associated
with inpatient hospitalization.442
ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION USING INTRA-
VENOUS BUSULFAN IN MYELOABLATIVE AND REDUCED-INTENSITY
CONDITIONING REGIMEN IN ACUTE LEUKEMIA PATIENTS. A COMPARI-
SON ANALYSIS WITH ORAL BUSULFAN
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Introduction: Recently oral Busulfan (OBu) has been replaced by
intravenous Bu (IVBu) in allogeneic stem cell transplantation
(HCT) conditioning regimens in acute leukaemia (AL) due more
predictable pharmacokinetic and lower toxicity.
Patients andMethods:We present results from a single centre, ret-
rospective study, using IVBu vs OBu plus Fludarabine (Flu) or Cy-
clofosfamide (Cy) as a reduced-intensity (RIC) and myeloablative
conditioning regimen in AL patients.
We analyzed 66 patients, from 2000 to 2010, with a median age 45
(8-71) years, 27 patients received HCTwith RIC, Flu 150 mg/m2 in
5 days and IVBu 8,2 mg/m2 or OBu 10 mg/kg in 3 days and 39 pa-
tients received HCTwith myeloablative Cy 120 mg/kg in 2 days and
IVBu 12,8 mg/m2 or OBu 16 mg/kg in 4 days.
Results: All patients grafted as follows: neutrophils. 0.5 x 109/l at
a median of 17 days and platelet. 20 x 109/l at 21 days. Fifteen pa-
tients (23%) showed acute GVHD grade III-IV, 17 (26%) chronic
GVHD, 15 (23%) liver dysfunction and 8 (12%) EVOH. There
were not differences in liver disease after HCT between two groups
(IVBu vs OBu) and also in incidence of infections and relapse. With
a median follow-up for alive patients of 54 months (15-120), 4-year
overall survival was 39% and 50% for OBu and IVBu, respectively (p
5 0.36) with no differences between the conditioning regimens
groups. 4-year progression-free survival was 81% and 54% for
OBu and IVBu, respectively (p 5 309).Relapse rate (28%) and non-related relapse toxicity (20%) do not
be higher than what we had observed with the standard regimen with
OBu (13% and 42% respectively).
Conclusions: Intravenous Busulfan is an effective drug in both reg-
imens for patients with acute leukemia. Mortality related to relapse
and toxicity do not appear to be higher than those observed with
oral Busulfan regimens.443
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Background: Idiopathic pneumonia syndrome (IPS) and diffuse al-
veolar hemorrhage (DAH) are non-infectious pulmonary complica-
tions of hematopoietic stem cell transplantation (HSCT) with
unclear pathogenesis and treatment.
Objective and method: To investigate the incidence and clinical
features of IPS/DAH after unrelated cord blood transplantation
(uCBT), we retrospectively analyzed 370 patients underwent
uCBT from January 2005 to June 2010 at ToranomonHospital. Di-
agnosis of IPS/DAH was made by multilobar infiltrates on CXR or
CT, clinical signs of pneumonia: cough, dyspnea, or rales, abnormal
physiology: increased arterial-alveolar oxygen gradient, or the need
for supplemental oxygen support, and no evidence of respiratory
tract infection.
Result: Twenty five cases of IPS/DAH were identified, with inci-
dence of 6.8%. The median-age was 59 years (range; 26-72). Nine-
teen patients underwent transplantation for leukemia, 4 for
malignant lymphoma, and 2 for aplastic anemia. IPS/DAHwas diag-
nosed at a median of 34 days (range; 8-93) after uCBT. All patients
were administered mPSL therapy. Nine of 25 patients were admin-
istered etanercept combined with mPSL pulse therapy. Five of 9 had
not responded, while 4 responders had worse their respiratory con-
dition after discontinuation of etanercept therapy. Twenty four of 25
died of respiratory failure.
Conclusion: IPS /DAH after uCBT are fetal pulmonary complica-
tions. It is suggested that the incidence of IPS/DAH after uCBT ap-
pears similar to that observed after transplantation using other
sources. But our results suggested that the existing treatment such
as etanercept combined mPSL pulse have only limited efficacy as
a therapy for IPS/DAH after uCBT. Further research is needed to
characterize the condition of this syndrome and to investigate the
optimal therapy and prophylaxis.
